Trial Profile
A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Parvovirus vaccine (Primary) ; MF 59
- Indications Parvovirus infections
- Focus Adverse reactions; Pharmacodynamics
- 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 Feb 2009 Status changed from suspended to completed, according to ClinicalTrials.gov.
- 17 Apr 2008 The expected completion date for this trial is now 1 Sep 2009.